The real-life approach of our study enhances the relevance of the results and provides a better understanding of how different metformin dosages and the presence of hyperprolactinemia influence galectin-3 levels, potentially leading to more personalized therapeutic strategies. Here, LGALS3 is linked to hyperprolactinemia.